Objective:Maintenance treatment with rituximab has been used in some nodal lymphomas,such as follicular and diffuse large cell lymphoma.The aim of this study was to evaluate the survival of extra nodal lymphoma patien...Objective:Maintenance treatment with rituximab has been used in some nodal lymphomas,such as follicular and diffuse large cell lymphoma.The aim of this study was to evaluate the survival of extra nodal lymphoma patients under maintenance treatment.Materials and methods:From July 2008 to December 2017,after induction treatment in patients with extra nodal lymphoma,if the patients consented and the drug was available,they were treated with rituximab every 3 months for 2 years.Results:A total of 112 patients with extra nodal lymphoma met the inclusion criteria.Among them,89 patients had high-grade lymphomas and 23 patients were in the group of low-grade lymphomas.The group of patients with high-grade lymphoma who received the rituximab-containing regimen as a maintenance treatment had lower rates of recurrence and death compared to the group that received rituximab only in the induction phase.In patients with low-grade lymphoma,the recurrence rate and mortality were also lower in the group receiving maintenance treatment compared to other groups,but the difference was not statistically significant.Conclusion:The use of rituximab in patients with extra nodal lymphoma as maintenance can increase the survival of the patients.展开更多
Objective:The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine,cisplatin,and 21-h infusional 5-fluorouracil(5-FU)....Objective:The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine,cisplatin,and 21-h infusional 5-fluorouracil(5-FU).Methods:This study was a prospective,observational study at a medical center in Western Iran.The clinical and survival data from 25 patients treated with gemcitabine,cisplatin,and 21-h infusional 5-FU at our center were prospectively assessed.Patients received chemotherapy consisting of cycles of continuous infusion of 5-FU(650 mg/m^(2))for 21 h on Days 1,2,3,and 4.Gemcitabine was administered at a dose of 1 g/m^(2)on Days 1 and 8,and cisplatin was administered at a dose of 60 mg/m^(2)on Day 1,with granulocyte colony-stimulating factor(G-CSF)support.Each cycle was repeated every 21 days for 5−6 cycles.Results:A total of 25 patients with an age range of 39−73 years were studied.One out of the two patients with stageⅡcancer survived for more than 43 months.Four out of the 14 patients with stageⅢcancer survived for more than 15 months.Seventeen patients died,and eight subjects were alive at the end of the study.The mean and median of overall survival(OS)rates for the 25 patients were 20 and 12 months,respectively.The median progression-free survival(PFS)was 6 months.Conclusion:It seems that the triple therapy with gemcitabine,cisplatin,and infusional 5-FU afforded significant PFS and OS benefits in patients with advanced pancreatic cancer.展开更多
文摘Objective:Maintenance treatment with rituximab has been used in some nodal lymphomas,such as follicular and diffuse large cell lymphoma.The aim of this study was to evaluate the survival of extra nodal lymphoma patients under maintenance treatment.Materials and methods:From July 2008 to December 2017,after induction treatment in patients with extra nodal lymphoma,if the patients consented and the drug was available,they were treated with rituximab every 3 months for 2 years.Results:A total of 112 patients with extra nodal lymphoma met the inclusion criteria.Among them,89 patients had high-grade lymphomas and 23 patients were in the group of low-grade lymphomas.The group of patients with high-grade lymphoma who received the rituximab-containing regimen as a maintenance treatment had lower rates of recurrence and death compared to the group that received rituximab only in the induction phase.In patients with low-grade lymphoma,the recurrence rate and mortality were also lower in the group receiving maintenance treatment compared to other groups,but the difference was not statistically significant.Conclusion:The use of rituximab in patients with extra nodal lymphoma as maintenance can increase the survival of the patients.
文摘Objective:The purpose of this study was to assess clinical characteristics and survival of patients with advanced pancreatic cancer who were treated with gemcitabine,cisplatin,and 21-h infusional 5-fluorouracil(5-FU).Methods:This study was a prospective,observational study at a medical center in Western Iran.The clinical and survival data from 25 patients treated with gemcitabine,cisplatin,and 21-h infusional 5-FU at our center were prospectively assessed.Patients received chemotherapy consisting of cycles of continuous infusion of 5-FU(650 mg/m^(2))for 21 h on Days 1,2,3,and 4.Gemcitabine was administered at a dose of 1 g/m^(2)on Days 1 and 8,and cisplatin was administered at a dose of 60 mg/m^(2)on Day 1,with granulocyte colony-stimulating factor(G-CSF)support.Each cycle was repeated every 21 days for 5−6 cycles.Results:A total of 25 patients with an age range of 39−73 years were studied.One out of the two patients with stageⅡcancer survived for more than 43 months.Four out of the 14 patients with stageⅢcancer survived for more than 15 months.Seventeen patients died,and eight subjects were alive at the end of the study.The mean and median of overall survival(OS)rates for the 25 patients were 20 and 12 months,respectively.The median progression-free survival(PFS)was 6 months.Conclusion:It seems that the triple therapy with gemcitabine,cisplatin,and infusional 5-FU afforded significant PFS and OS benefits in patients with advanced pancreatic cancer.
